Publication | Open Access

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

Hematological MalignancyLymphoid NeoplasiaOncologyResource UtilizationCommercial Axicabtagene CiloleucelOutcomes ResearchMedicineRadiation Oncology